141 related articles for article (PubMed ID: 38888535)
1. The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?
Lala A; Mentz RJ; Santos-Gallego CG
J Am Coll Cardiol; 2024 Jul; 84(2):149-151. PubMed ID: 38888535
[No Abstract] [Full Text] [Related]
2. Importance of risk factor management in diabetic patients and reduction in Stage B heart failure.
Murtagh G; O Connell J; O Connell E; Tallon E; Watson C; Gallagher J; Baugh J; Patle A; O Connell L; Griffin J; O'Hanlon R; Voon V; Ledwidge M; O Shea D; McDonald K
QJM; 2015 Apr; 108(4):307-14. PubMed ID: 25239761
[TBL] [Abstract][Full Text] [Related]
3. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
Wenmeng W; Qizhu T
Med Hypotheses; 2011 Feb; 76(2):181-3. PubMed ID: 20932648
[TBL] [Abstract][Full Text] [Related]
4. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation.
Gopal K; Karwi QG; Tabatabaei Dakhili SA; Wagg CS; Zhang L; Sun Q; Saed CT; Panidarapu S; Perfetti R; Ramasamy R; Ussher JR; Lopaschuk GD
Cardiovasc Diabetol; 2023 Mar; 22(1):73. PubMed ID: 36978133
[TBL] [Abstract][Full Text] [Related]
5. Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
Sattar N; McGuire DK
Circulation; 2018 Jul; 138(1):7-9. PubMed ID: 29967228
[No Abstract] [Full Text] [Related]
6. Research digest: new horizons in heart failure therapy.
Sattar N; Preiss D
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):832. PubMed ID: 31621593
[No Abstract] [Full Text] [Related]
7. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin.
Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jun; 20(6):1367-1368. PubMed ID: 29377537
[No Abstract] [Full Text] [Related]
8. Diabetic cardiomyopathy.
Lee MMY; McMurray JJV; Lorenzo-Almorós A; Kristensen SL; Sattar N; Jhund PS; Petrie MC
Heart; 2019 Feb; 105(4):337-345. PubMed ID: 30337334
[No Abstract] [Full Text] [Related]
9. Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats.
Kumar S; Prasad S; Sitasawad SL
PLoS One; 2013; 8(7):e67009. PubMed ID: 23843977
[TBL] [Abstract][Full Text] [Related]
10. Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies.
Tarquini R; Pala L; Brancati S; Vannini G; De Cosmo S; Mazzoccoli G; Rotella CM
Curr Med Chem; 2018; 25(13):1510-1524. PubMed ID: 28685679
[TBL] [Abstract][Full Text] [Related]
11. Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications.
Paolillo S; Marsico F; Prastaro M; Renga F; Esposito L; De Martino F; Di Napoli P; Esposito I; Ambrosio A; Ianniruberto M; Mennella R; Paolillo R; Gargiulo P
Heart Fail Clin; 2019 Jul; 15(3):341-347. PubMed ID: 31079692
[TBL] [Abstract][Full Text] [Related]
12. Heart failure and diabetes - underestimated, underdiagnosed and poorly understood: A call for action.
Marx N
Diab Vasc Dis Res; 2017 Mar; 14(2):67-68. PubMed ID: 28128001
[No Abstract] [Full Text] [Related]
13. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
14. The novel function of citronellal for antidiabetic cardiomyopathy.
Qiu Y; Meng L; Chao C; Wang L; Wang Y; Liu T; Fu Y; Li Y; Song Y; Guo Y; Niu Q; Zhang J; Yin Y; Li P
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1731-1735. PubMed ID: 34596208
[No Abstract] [Full Text] [Related]
15. Taurine attenuates oxidative stress and alleviates cardiac failure in type I diabetic rats.
Wang GG; Li W; Lu XH; Zhao X; Xu L
Croat Med J; 2013 Apr; 54(2):171-9. PubMed ID: 23630144
[TBL] [Abstract][Full Text] [Related]
16. [Diabetes-related heart failure: role of coronary vascular events and diabetic cardiomyopathy].
Bando YK; Murohara T
Nihon Rinsho; 2016 Aug; 74 Suppl 6():469-72. PubMed ID: 30547539
[No Abstract] [Full Text] [Related]
17. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.
Januzzi JL; Butler J; Del Prato S; Ezekowitz JA; Ibrahim NE; Lam CSP; Lewis GD; Marwick TH; Rosenstock J; Tang WHW; Zannad F; Lawson F; Perfetti R; Urbinati A
Am Heart J; 2023 Feb; 256():25-36. PubMed ID: 36372245
[TBL] [Abstract][Full Text] [Related]
18. Diabetic cardiomyopathy.
Lorenzo-Almorós A; Cepeda-Rodrigo JM; Lorenzo Ó
Rev Clin Esp (Barc); 2022 Feb; 222(2):100-111. PubMed ID: 35115137
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach.
Dei Cas A; Spigoni V; Ridolfi V; Metra M
Endocr Metab Immune Disord Drug Targets; 2013 Mar; 13(1):38-50. PubMed ID: 23369136
[TBL] [Abstract][Full Text] [Related]
20. Low-dose copper infusion into the coronary circulation induces acute heart failure in diabetic rats: New mechanism of heart disease.
Cheung CC; Soon CY; Chuang CL; Phillips AR; Zhang S; Cooper GJ
Biochem Pharmacol; 2015 Sep; 97(1):62-76. PubMed ID: 26208785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
